ÖZTEMÜR, Z. Et Al. 2012. The effect of intravenous pamidronate treatment for type i osteogenesis imperfecta patients have on their bone mineral density, fracture rate, and mobility. HEALTHMED , vol.6, no.10 , 3425-3429.

ÖZTEMÜR, Z., ÖZTÜRK, H., Circi, E., BULUT, O., ÜNER, S., ALTUN, A., ... Tezeren, G.(2012). The effect of intravenous pamidronate treatment for type i osteogenesis imperfecta patients have on their bone mineral density, fracture rate, and mobility. HEALTHMED , vol.6, no.10, 3425-3429.

ÖZTEMÜR, ZEKERİYA Et Al. "The effect of intravenous pamidronate treatment for type i osteogenesis imperfecta patients have on their bone mineral density, fracture rate, and mobility," HEALTHMED , vol.6, no.10, 3425-3429, 2012

ÖZTEMÜR, ZEKERİYA Et Al. "The effect of intravenous pamidronate treatment for type i osteogenesis imperfecta patients have on their bone mineral density, fracture rate, and mobility." HEALTHMED , vol.6, no.10, pp.3425-3429, 2012

ÖZTEMÜR, Z. Et Al. (2012) . "The effect of intravenous pamidronate treatment for type i osteogenesis imperfecta patients have on their bone mineral density, fracture rate, and mobility." HEALTHMED , vol.6, no.10, pp.3425-3429.

@article{article, author={ZEKERİYA ÖZTEMÜR Et Al. }, title={The effect of intravenous pamidronate treatment for type i osteogenesis imperfecta patients have on their bone mineral density, fracture rate, and mobility}, journal={HEALTHMED}, year=2012, pages={3425-3429} }